Research progress on the effect of drug therapy on the physical growth of children and adolescents with attention-deficit/hyperactivity disorder

DENG Lan-liu; CHEN Li

doi:10.11852/zgetbjzz2021-0395

PDF(571 KB)

Chinese Journal of Child Health Care ›› 2022, Vol. 30 ›› Issue (8) : 874-878. DOI: 10.11852/zgetbjzz2021-0395

Review

Research progress on the effect of drug therapy on the physical growth of children and adolescents with attention-deficit/hyperactivity disorder

DENG Lan-liu, CHEN Li

Author information +

History +

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a common chronic neurodevelopmental disorder in childhood, which has a significant impact on children's academic performance, interpersonal communication, social functioning, as well as the whole family and society.The incidence of ADHD has been on the rise over the past few decades.Stimulants such as methylphenidate (MPH) and selective norepinephrine reuptake inhibitors such as atomoxetine (ATX), are both commonly used drugs in ADHD treatment.Parents are concerned about the possible negative effects of medication on the physical growth of ADHD children.This article reviews the effects, mechanisms and management of drug therapy on the physical growth of ADHD children, in order to improve the compliance of clinical drug therapy.

Key words

attention-deficit/hyperactivity disorder / drug therapy / physical growth / management

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

DENG Lan-liu, CHEN Li. Research progress on the effect of drug therapy on the physical growth of children and adolescents with attention-deficit/hyperactivity disorder[J]. Chinese Journal of Child Health Care. 2022, 30(8): 874-878 https://doi.org/10.11852/zgetbjzz2021-0395

References

[1] Cortese S.Pharmacologic treatment of attention deficit-hyperactivity disorder[J].N Engl J Med, 2020, 383(11):1050-1056.
[2] Wang T, Liu K, Li Z, et al.Prevalence of attention deficit/hyperactivity disorder among children and adolescents in China:A systematic review and meta-analysis[J].BMC psychiatry, 2017, 17(1):32.
[3] Wolraich ML, Chan E, Froehlich T, et al.ADHD diagnosis and treatment guidelines:A historical perspective[J].Pediatrics, 2019, 144(4):e20191682.
[4] Faraone SV, Asherson P, Banaschewski T, et al.Attention-deficit/hyperactivity disorder[J].Nat Rev Dis Primers, 2015, 1:15020.
[5] 中华医学会儿科学分会发育行为学组.注意缺陷多动障碍早期识别、规范诊断和治疗的儿科专家共识[J].中华儿科杂志, 2020, 58(3):188-193.
[6] Beau-Lejdstrom R, Douglas I, Evans SJ, et al.Latest trends in ADHD drug prescribing patterns in children in the UK:Prevalence, incidence and persistence[J].BMJ Open, 2016, 6(6):e010508.
[7] Bachmann CJ,Wijlaars LP, Kalverdijk LJ, et al.Trends in ADHD medication use in children and adolescents in five western countries, 2005—2012[J].Eur Neuropsychopharmacol, 2017, 27(5):484-493.
[8] Man KKC, Ip P, Hsia Y, et al.ADHD drug prescribing trend is increasing among children and adolescents in hong kong[J].J Atten Disord, 2017, 21(14):1161-1168.
[9] Raman SR, Man KKC, Bahmanyar S, et al.Trends in attention-deficit hyperactivity disorder medication use:A retrospective observational study using population-based databases[J].Lancet Psychiatry, 2018, 5(10):824-835.
[10] Klein R, Mannuzza S.Hyperactive boys almost grown up: Ⅲ.Methylphenidate effects on ultimate height[J].Arch Gen Psychiatry, 1988, 45(12):1131-1134.
[11] Safer D, Allen R, Barr E.Growth rebound after termination of stimulant drugs[J].J Pediatr, 1975, 86(1):113-116.
[12] Faraone SV, Biederman J, Morley CP, et al.Effect of stimulants on height and weight:A review of the literature[J].J Am Acad Child Adolesc Psychiatry, 2008, 47(9):994-1009.
[13] Díez-Suárez A, Vallejo-Valdivielso M, Marín-Méndez JJ, et al.Weight, height, and body mass index in patients with attention-deficit/hyperactivity disorder treated with methylphenidate[J].J Child Adolesc Psychopharmacol, 2017, 27(8):723-730.
[14] Durá-Travé T, Yoldi-Petri ME, Gallinas-Victoriano F, et al.Effects of osmotic-release methylphenidate on height and weight in children with attention-deficit hyperactivity disorder (ADHD) following up to four years of treatment[J].J Child Neurol, 2012, 27(5):604-609.
[15] Kim HW, Kim SO, Shon S, et al.Effect of methylphenidate on height and weight in Korean children and adolescents with attention-deficit/hyperactivity disorder:A retrospective chart review[J].J Child Adolesc Psychopharmacol, 2014, 24(8):448-453.
[16] Koonrungsesomboon K, Koonrungsesomboon N.The effects of methylphenidate treatment on child growth in thai children and adolescents with attention-deficit/hyperactivity disorder[J].J Child Adolesc Psychopharmacol, 2020, 30(3): 189-197.
[17] Faraone SV, Giefer EE.Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth[J].J Am Acad Child Adolesc Psychiatry, 2007, 46(9):1138-1147.
[18] Zachor DA, Roberts AW, Hodgens JB, et al.Effects of long-term psychostimulant medication on growth of children with ADHD[J].Res Dev Disabil, 2006, 27(2):162-174.
[19] 陈立.影响注意缺陷多动障碍的营养因素及管理[J].教育生物学杂志, 2020,8(2):87-93.
[20] Biederman J, Spencer TJ, Monuteaux MC, et al.A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: Sex and treatment effects[J].J Pediatr, 2010, 157(4):635-640.
[21] Zhang H, Du M, Zhuang S.Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD[J].Neuropediatrics, 2010, 41(2): 55-59.
[22] Lentferink YE, van de Garde EMW, Knibbe CAJ, et al.Psychostimulants:Influence on body mass index and height in a pediatric population with attention-deficit/hyperactivity disorder?[J].J Child Adolesc Psychopharmacol, 2018, 28(8):530-536.
[23] Erhart M, Herpertz-Dahlmann B, Wille N, et al.Examining the relationship between attention-deficit/hyperactivity disorder and overweight in children and adolescents[J].Eur Child Adolesc Psychiatry, 2012, 21(1):39-49.
[24] Racicka E, Hanc T, Giertuga K, et al.Prevalence of overweight and obesity in children and adolescents with ADHD:The significance of comorbidities and pharmacotherapy[J].J Atten Disord, 2018, 22(12):1095-1108.
[25] Lingineni RK, Biswas S, Ahmad N, et al.Factors associated with attention deficit/hyperactivity disorder among US children:Results from a national survey[J].BMC Pediatr.2012, 12:50.
[26] Poulton AS, Bui Q, Melzer E, et al.Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder:A prospective cohort study[J].Int Clin Psychopharmacol, 2016, 31(2):93-99.
[27] Hanc' T, Cies'lik J, Wolańczyk T, et al.Assessment of growth in pharmacological treatment-naÏve Polish boys with attention-deficit/hyperactivity disorder[J].J Child Adolesc Psychopharmacol, 2012, 22(4):300-306.
[28] Harstad EB, Weaver AL, Katusic SK, et al.ADHD, stimulant treatment, and growth:A longitudinal study[J].Pediatrics, 2014, 134(4):e935-e944.
[29] Greenhill LL, Swanson JM, Hechtman L, et al.Trajectories of growth associated with long-term stimulant medication in the multimodal treatment study of attention-deficit/hyperactivity disorder[J].J Am Acad Child Adolesc Psychiatry, 2020, 59(8):978-989.
[30] Spencer TJ, Kratochvil CJ, Sangal RB, et al.Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment[J].J Child Adolesc Psychopharmacol, 2007, 17(5):689-700.
[31] Kratochvil CJ, Wilens TE, Greenhill LL, et al.Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder[J].J Am Acad Child Adolesc Psychiatry, 2006, 45(8):919-927.
[32] Kweon K, Yoon JS, Park KJ, et al.Effects of atomoxetine on height and weight in korean children and adolescents with attention-deficit/hyperactivity disorder:A retrospective chart review[J].Psychiatry Investig, 2018, 15(6):649-654.
[33] Gurbuz F, Gurbuz BB, Celik GG, et al.Effects of methylphenidate on appetite and growth in children diagnosed with attention deficit and hyperactivity disorder[J].J Pediatr Endocrinol Metab, 2016, 29(1):85-92.
[34] Bou Khalil R, Fares N, Saliba Y, et al.The effect of methylphenidate on appetite and weight[J].Encephale, 2017, 43(6):577-581.
[35] Lee SI, Hong SD, Kim SY, et al.Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder[J].Prog Neuropsychopharmacol Biol psychiatry, 2007, 31(1):210-216.
[36] Graham J, Banaschewski T, Buitelaar J, et al.European guidelines on managing adverse effects of medication for ADHD[J].Eur Child Adolesc Psychiatry, 2011, 20(1):17-37.
[37] Faraone SV.The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities[J].Neurosci Biobehav Rev, 2018, 87:255-270.
[38] Uddin SMZ, Robison LS, Fricke D, et al.Methylphenidate regulation of osteoclasts in a dose- and sex-dependent manner adversely affects skeletal mechanical integrity[J].Sci Rep, 2018, 8(1):1515.
[39] Thanos PK, Robison LS, Steier J, et al.A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior[J].Pharmacol Biochem Behav, 2015, 131(undefined):143-153.
[40] Wang J, Adab P, Liu W, et al.Prevalence of adiposity and its association with sleep duration, quality, and timing among 9-12-year-old children in Guangzhou, China[J].J Epidemiol, 2017, 27(11):531-537.
[41] Michelson D, Read HA, Ruff DD, et al.CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD[J].J Am Acad Child Adolesc Psychiatry, 2007, 46(2):242-251.
[42] Martins S, Tramontina S, Polanczyk G, et al.Weekend holidays during methylphenidate use in ADHD children:A randomized clinical trial[J].J Child Adolesc Psychopharmacol, 2004, 14(2):195-206.
[43] Waxmonsky JG, Baweja R.Editorial: does an attention-deficit/hyperactivity disorder pill a day keep failing grades away?[J].J Am Acad Child Adolesc Psychiatry, 2019, 58(4):395-397.
[44] Cortese S, Holtmann M, Banaschewski T, et al.Practitioner review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents[J].J Child Psychol Psychiatry, 2013, 54(3):227-246.